Literature DB >> 7815309

Application of optimal sampling theory to the determination of metacycline pharmacokinetic parameters: effect of model misspecification.

M Tod1, C Padoin, K Louchahi, B Moreau-Tod, O Petitjean, G Perret.   

Abstract

Use of optimal sampling theory (OST) in pharmacokinetic studies allows the number of sampling times to be greatly reduced without loss in parameter estimation precision. OST has been applied to the determination of the bioavailability parameters (area under the curve (AUC), maximal concentration (Cmax), time to reach maximal concentration (Tmax), elimination half-life (T1/2), of metacycline in 16 healthy volunteers. Five different models were used to fit the data and to define the optimal sampling times: one-compartment first-order, two-compartment first-order, two-compartment zero-order, two-compartment with Michaelis-Menten absorption kinetics, and a stochastic model. The adequacy of these models was first evaluated in a 6-subject pilot study. Only the stochastic model with zero-order absorption kinetics was adequate. Then, bioavailability parameters were estimated in a group of 16 subjects by means of noncompartmental analysis (with 19 samples per subject) using each optimal sampling schedule based procedure (with 6 to 9 samples depending on the model). Bias (PE) and precision (RMSE) of each bioavailability parameter estimation were calculated by reference to noncompartmental analysis, and were satisfactory for the 3 adequate models. The most relevant criteria for discrimination of the best model were the coefficient of determination, the standard deviation, and the mean residual error vs. time plot. Additional criteria were the number of required sampling times and the coefficient of variation of the estimates. In this context, the stochastic model was superior and yielded very good estimates of the bioavailability parameters with only 8 samples per subject.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7815309     DOI: 10.1007/bf02353539

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  14 in total

1.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  Estimate of the number and of the temporal sequence of measurements in a kinetic experiment.

Authors:  R Gomeni
Journal:  Fundam Clin Pharmacol       Date:  1990       Impact factor: 2.748

3.  The influence of assay variability on pharmacokinetic parameter estimation.

Authors:  D A Graves; C S Locke; K T Muir; R P Miller
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

4.  Saturable rate of cefatrizine absorption after oral administration to humans.

Authors:  B G Reigner; W Couet; J P Guedes; J B Fourtillan; T N Tozer
Journal:  J Pharmacokinet Biopharm       Date:  1990-02

5.  Pharmacokinetic stochastic model with Weibull-distributed residence times of drug molecules in the body.

Authors:  V K Piotrovskii
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon.

Authors:  R L Oberle; G L Amidon
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

7.  [Value of the theory of the optimal sampling scheme for bioequivalence studies].

Authors:  M Tod; O Petitjean; P Nicolas
Journal:  Therapie       Date:  1993 Jan-Feb       Impact factor: 2.070

8.  Analysis of pharmacokinetic data using parametric models. II. Point estimates of an individual's parameters.

Authors:  L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1985-10

9.  An evaluation of optimal sampling strategy and adaptive study design.

Authors:  G L Drusano; A Forrest; M J Snyder; M D Reed; J L Blumer
Journal:  Clin Pharmacol Ther       Date:  1988-08       Impact factor: 6.875

10.  A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients.

Authors:  G L Drusano; A Forrest; K I Plaisance; J C Wade
Journal:  Clin Pharmacol Ther       Date:  1989-06       Impact factor: 6.875

View more
  3 in total

1.  Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.

Authors:  Andrew Hooker; Paolo Vicini
Journal:  AAPS J       Date:  2005-11-01       Impact factor: 4.009

2.  Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.

Authors:  M Tod; J M Rocchisani
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

3.  Limited-sampling strategies for anti-infective agents: systematic review.

Authors:  Denise A Sprague; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2009-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.